METHODS	In a multicenter two-arm phase II trial , patients were randomized to receive oxaliplatin 130 mg/m ( 2 ) on day 1 and capecitabine 1000 mg/m ( 2 ) twice daily on days 1-14 every 3 weeks alone or in combination with standard dose cetuximab .\